enGene Therapeutics Inc. Common Stock ENGN
i
Market datapartial · fetched 2026-11-12T03:21:32.329Z
Delta surfaceAlpaca · derived absolute-delta buckets · 2026-12-18
Calculation methodologyOptions historyIV: ThetaData historical Greeks, equal-weight mean of call/put 50-delta IV across the next four listed Friday-cycle expirations, including holiday shifts verified against ThetaData’s market calendar. Missing inputs leave gaps. Skew: equal-weight mean of put minus call IV across those four expirations. IV-implied move history: mean of each expiration’s average call/put IV multiplied by the square root of remaining calendar days divided by 365.25; percentage of spot, not a quoted straddle premium.
History dataPriceAlpaca · sip · 2026-11-12T00:59:07.945647626Z
FundamentalsAlpha Vantage · unavailable
enGene Therapeutics Inc. Common Stock options
Table
| Delta | Calls | Puts | ||||
|---|---|---|---|---|---|---|
| Pseudo strike | IV | B/E move | Pseudo strike | IV | B/E move | |
| 20Δ | 2.62 | 713.1% | 64.8% | |||
| 25Δ | 2.84 | 613.1% | 56.6% | |||
| 30Δ | 3.05 | 529.8% | 49.1% | |||
| 35Δ | 3.26 | 495.4% | 43.4% | |||
| 40Δ | 3.47 | 461.0% | 37.8% | |||
| 45Δ | 3.67 | 426.5% | 32.1% | |||
| 50Δ | 3.88 | 392.1% | 26.4% | |||
| 55Δ | 4.07 | 362.7% | 21.8% | |||
| 60Δ | 4.24 | 340.4% | 18.6% | |||
| 65Δ | 4.40 | 318.2% | 15.3% | |||
| 70Δ | 4.57 | 296.0% | 12.1% | |||
| 75Δ | 4.74 | 273.8% | 8.9% | |||
| 80Δ | 4.90 | 251.5% | 5.7% | |||
20Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.62
- IV
- 713.1%
- B/E move
- 64.8%
25Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 2.84
- IV
- 613.1%
- B/E move
- 56.6%
30Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.05
- IV
- 529.8%
- B/E move
- 49.1%
35Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.26
- IV
- 495.4%
- B/E move
- 43.4%
40Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.47
- IV
- 461.0%
- B/E move
- 37.8%
45Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.67
- IV
- 426.5%
- B/E move
- 32.1%
50Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 3.88
- IV
- 392.1%
- B/E move
- 26.4%
55Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.07
- IV
- 362.7%
- B/E move
- 21.8%
60Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.24
- IV
- 340.4%
- B/E move
- 18.6%
65Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.40
- IV
- 318.2%
- B/E move
- 15.3%
70Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.57
- IV
- 296.0%
- B/E move
- 12.1%
75Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.74
- IV
- 273.8%
- B/E move
- 8.9%
80Δ
- Pseudo strike
- IV
- B/E move
- Pseudo strike
- 4.90
- IV
- 251.5%
- B/E move
- 5.7%
Options history
No recorded observations
Biotechnology
ENTA
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company is…
More →ENTX
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies for unmet medical…
More →ERAS
Erasca Inc. is a pioneering biopharmaceutical firm specializing in the development of targeted therapies for genetically defined cancers, aiming to meet significant unmet needs in…
More →EVMN
Evommune, Inc. is an innovative biotechnology company focused on developing cutting-edge therapeutics for immunological disorders, targeting significant unmet medical needs in…
More →EWTX
Edgewise Therapeutics, Inc., a biopharmaceutical company, develops small molecule therapies for musculoskeletal diseases. The company is headquartered in Boulder, Colorado.
More →EXEL
Exelixis, Inc., an oncology-focused biotechnology company, is focused on the discovery, development, and commercialization of new drugs to treat cancers in the United States. The…
More →